AeroVironment reports after the close today with the stock down 17% on the week — but the more telling story is what happened in the lending market over the past fortnight.
The borrow setup has undergone a dramatic swing. Just two weeks ago, availability had tightened to under 9% — meaning only one share was available to borrow for every ten already lent out, the tightest the lending pool had been all year. Then, between August 13 and August 14, availability jumped from 16% to 75% in a single session. It has since settled back to around 57%, still well within the "tight" range but dramatically looser than the near-squeeze conditions that persisted through late July and the first week of August. That flush in availability coincided with short interest edging down roughly 1% on the week to 8.5% of the free float — still a meaningful position for a mid-cap defense name, but no longer accelerating. Cost to borrow has ticked up 12% on the week to 0.56%, yet remains historically low. The net read: shorts were aggressively positioned heading into earnings, then some of that pressure was relieved — though the position remains large enough to matter if the print surprises.
Options traders are not sounding a sharp alarm. The put/call ratio of 0.71 is almost exactly in line with its 20-day average of 0.70, with a z-score barely above zero. That is a notably calm reading given the stock's 17% weekly slide; the absence of outsized put demand suggests the market has largely priced in whatever damage was done this week rather than bracing for further downside on the print. The PCR sits well below the 52-week high of 1.08, which would mark genuine defensive crowding. For now, options positioning looks neutral rather than fearful.
The Street remains broadly constructive, but recent analyst activity tells a story of calibration rather than conviction. The cluster of moves from early July — after the previous earnings print — saw multiple firms trim targets, with RBC cutting its rating to Sector Perform and Citizens dropping its target from $350 to $230. Raymond James upgraded to Outperform on July 16 with a $210 target. The consensus points to a mean target of $232, implying roughly 44% upside from the current $160 level. That gap is wide — but it reflects the stock's 17% drop this week rather than a sudden surge in optimism. The bull case centers on 20% organic revenue growth and a projected 18% CAGR toward $50 billion in addressable market by FY30. The bear case flags lumpy defense contract timing, BlueHalo integration risk, and a customer base concentrated around DoD procurement cycles. At a trailing P/E of 48.6x and EV/EBITDA of 26.3x, the valuation demands execution — and the P/E has expanded by roughly 12 points over the past 30 days purely because the stock has fallen faster than earnings estimates.
The earnings history adds genuine texture here. The most recent prior print on July 8 delivered an 8.7% one-day decline and a 13.1% five-day loss. The print before that — June 29 — produced a 19.7% one-day gain and a 28.2% five-day rally. That kind of binary outcome history, with swings of 9% to 20% in either direction, explains why the ORTEX short score has been running in the mid-60s. The factor scores reinforce the caution: the short score ranks in just the 5th percentile of the universe, and days-to-cover sits in the 10th percentile. EPS momentum has softened to the 7th percentile on a 90-day basis. What moves today after the bell will determine whether the borrow-market flush of last week was prescient positioning ahead of a beat — or an early exit that costs short sellers on a miss.
Peer context is equally sobering: MRCY fell 17.8% on the week, RCAT dropped 13.6%, and KTOS lost 11.5%, suggesting sector-wide pressure rather than AVAV-specific weakness — which makes the magnitude of tonight's reaction more about what management says about the second half than about any single line in the income statement.
See the live data behind this article on ORTEX.
Open AVAV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
